279 related articles for article (PubMed ID: 21147249)
1. [Onychomycosis-causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds].
Manzano-Gayosso P; Méndez-Tovar LJ; Arenas R; Hernández-Hernández F; Millán-Chiu B; Torres-Rodríguez JM; Cortés-González E; Fernández R; López-Martínez R
Rev Iberoam Micol; 2011; 28(1):32-5. PubMed ID: 21147249
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
3. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
[TBL] [Abstract][Full Text] [Related]
4. [Species distribution and antifungal susceptibilities of yeast clinical isolates from three hospitals in Korea, 2001 to 2007].
Lee MK; Yong D; Kim M; Kim MN; Lee K
Korean J Lab Med; 2010 Aug; 30(4):364-72. PubMed ID: 20805708
[TBL] [Abstract][Full Text] [Related]
5. [Multicenter study of fungemia due to yeasts in Argentina].
Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A;
Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638
[TBL] [Abstract][Full Text] [Related]
6. [Antifungal susceptibility of emerging yeast pathogens].
García-Martos P; Domínguez I; Marín P; García-Agudo R; Aoufi S; Mira J
Enferm Infecc Microbiol Clin; 2001; 19(6):249-56. PubMed ID: 11440661
[TBL] [Abstract][Full Text] [Related]
7. Fluconazole and itraconazole resistance of yeasts isolated from the bloodstream and catheters of hospitalized pediatric patients.
Giusiano G; Mangiaterra M; Garcia Saito V; Rojas F; Gómez V; Díaz MC
Chemotherapy; 2006; 52(5):254-9. PubMed ID: 16899974
[TBL] [Abstract][Full Text] [Related]
8. Antifungal susceptibility patterns of yeasts and filamentous fungi isolated from nail infection.
Ataides FS; Chaul MH; El Essal FE; Costa CR; Souza LK; Fernandes OF; Silva MR
J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1479-85. PubMed ID: 22049990
[TBL] [Abstract][Full Text] [Related]
9. Oral Candida isolates among HIV-infected subjects in Nigeria.
Nweze EI; Ogbonnaya UL
J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
[TBL] [Abstract][Full Text] [Related]
10. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina.
Córdoba S; Vivot W; Bosco-Borgeat ME; Taverna C; Szusz W; Murisengo O; Isla G; Davel G;
Rev Argent Microbiol; 2011; 43(3):176-85. PubMed ID: 22430989
[TBL] [Abstract][Full Text] [Related]
11. Yeasts as important agents of onychomycosis: in vitro activity of propolis against yeasts isolated from patients with nail infection.
Khosravi AR; Shokri H; Nikaein D; Mansouri P; Erfanmanesh A; Chalangari R; Katalin M
J Altern Complement Med; 2013 Jan; 19(1):57-62. PubMed ID: 22954465
[TBL] [Abstract][Full Text] [Related]
12. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
13. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey.
Kuzucu C; Durmaz R; Otlu B; Aktas E; Gulcan H; Cizmeci Z
New Microbiol; 2008 Jul; 31(3):401-8. PubMed ID: 18843896
[TBL] [Abstract][Full Text] [Related]
14. [In vitro activities of posaconazole, fluconazole, itraconazole, ketoconazole and voriconazole against Candida glabrata].
Blanco MT; Cañadas J; García-Martos P; Marín P; García-Tapia A; Rodríguez J
Rev Esp Quimioter; 2009 Sep; 22(3):139-43. PubMed ID: 19662547
[TBL] [Abstract][Full Text] [Related]
15. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test.
Nenoff P; Oswald U; Haustein UF
Mycoses; 1999; 42(11-12):629-39. PubMed ID: 10680439
[TBL] [Abstract][Full Text] [Related]
17. [Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use].
Saporiti AM; Gómez D; Levalle S; Galeano M; Davel G; Vivot W; Rodero L
Rev Argent Microbiol; 2001; 33(4):217-22. PubMed ID: 11833253
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999-2001].
Mujica MT; Finquelievich JL; Jewtuchowicz V; Iovannitti CA
Rev Argent Microbiol; 2004; 36(3):107-12. PubMed ID: 15559191
[TBL] [Abstract][Full Text] [Related]
19. [Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents].
García Heredia M; García SD; Copolillo EF; Cora Eliseth M; Barata AD; Vay CA; de Torres RA; Tiraboschi N; Famiglietti AM
Rev Argent Microbiol; 2006; 38(1):9-12. PubMed ID: 16784126
[TBL] [Abstract][Full Text] [Related]
20. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].
Linares MJ; Charriel G; Solís F; Casal M
Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):493-7. PubMed ID: 14572382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
